Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 3, 2026

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson therapy nipocalimab granted U.S…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Through close collaboration with the FDA, we seek to advance the development of nipocalimab as a potential new treatment option for the SLE patient community
80% confidence
Nipocalimab is the only FcRn blocker to demonstrate reduction in SLE disease activity, as shown in the JASMINE study
80% confidence
Systemic lupus erythematosus is a serious, complex disease that affects many aspects of a patient's life, and treatment options remain limited
80% confidence
Progress like this brings renewed hope for more targeted therapies and meaningful outcomes for people living with this devastating disease
80% confidence
Nipocalimab earning its fifth FDA Fast Track designation, now in systemic lupus erythematosus, reflects the importance of accelerating the delivery of an immunoselective therapy that could fill an unmet need in this serious condition
80% confidence